KarXT
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bipolar-I Disorder With Mania or Mania With Mixed Features
Conditions
Bipolar-I Disorder With Mania or Mania With Mixed Features
Trial Timeline
Jun 11, 2025 → Nov 1, 2026
NCT ID
NCT06951698About KarXT
KarXT is a phase 3 stage product being developed by Bristol Myers Squibb for Bipolar-I Disorder With Mania or Mania With Mixed Features. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06951698. Target conditions include Bipolar-I Disorder With Mania or Mania With Mixed Features.
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07288567 | Phase 3 | Recruiting |
| NCT07061288 | Phase 1 | Recruiting |
| NCT06951711 | Phase 3 | Recruiting |
| NCT06951698 | Phase 3 | Recruiting |
| NCT06882785 | Phase 3 | Recruiting |